🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06108830
Recruiting Not applicable

Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients

NCT06108830 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Medical University General Hospital
Phase
Not applicable
Started
2023-12-01
Last updated
2024-09-04

Condition(s) studied

Sleep Disturbance

Investigational drug(s) / intervention(s)

EsketamineRemimazolamEsketamine and remimazolamnormal saline

Esketamine: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began

Remimazolam: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began

Esketamine and remimazolam: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began

normal saline: Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began

Study summary

To explore the effects of esketamine combined with remimazolam on postoperative sleep disturbance and anxiety in surgical patients undergoing gastroenteroscopies

Eligibility

Sex
ALL
Min age
20 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 20-65 years old; 2. ASA classification is grade I-III; 3. Elective surgery is proposed 4. BMI of 19-30 kg/m2; 5. Patients who agreed to enroll in this study voluntarily Exclusion Criteria: 1. Those who are known to be allergic to the drug ingredients in this study and their allergic constitution; 2. Allergic history of general anesthesia drugs, opioid drugs, non-steroidal drugs; 3. History of neurological diseases; History of chronic pain; Drug and alcohol addiction; A long history of opioid use; Opiates were given 48 hours before surgery; 4. ASA rating of IV or V; 5. Coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, electrolyte abnormalities; 6. History of gastrointestinal disease (peptic ulcer, Crohn's disease, ulcerative colitis); 7. Respiratory insufficiency, respiratory failure; 8. Patients who refused to use intravenous PCA for analgesia; 9. Pregnant or lactating women; 10. BMI\<18 kg/m2 or BMI\>30kg/m2; 11. Poor compliance, unable to complete the experiment according to the study plan; 12. Participants who have participated in clinical trials of other drugs within the last 4 weeks; 13. Any circumstances deemed unsuitable for inclusion by the researcher for any reason.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tianjin Medical University General Hospital Tianjin China Recruiting

More Tianjin Medical University General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06108830 on ClinicalTrials.gov ↗ ← All trials in China